Phenytek and Keppra drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Phenytek (phenytoin sodium) and Keppra (levetiracetam). Common drug interactions include cardiac failure among females and cerebellar atrophy among males.

The phase IV clinical study analyzes what interactions people have when they take Phenytek and Keppra. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Phenytek?

Phenytek has active ingredients of phenytoin sodium. It is often used in seizures. eHealthMe is studying from 167 Phenytek users. Check the latest studies of Phenytek.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.



On Jul, 17, 2026

23 people who take Phenytek and Keppra together, and have interactions are studied.

Phenytek and Keppra drug interactions.

What are the common drug interactions of Phenytek and Keppra, by gender? *:

female:

  1. Cardiac failure
  2. Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
  3. General physical condition
  4. Malaise (a feeling of general discomfort or uneasiness)
  5. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  6. Abdominal pain upper
  7. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  8. Anticonvulsant drug level below therapeutic
  9. Anxiety
  10. Burning sensation

male:

  1. Cerebellar atrophy (degeneration of the section of the brain responsible for balance, voluntary muscle movements)
  2. Gingival hypertrophy (overgrowth of gums)
  3. Neuropathy peripheral (surface nerve damage)
  4. Speech disorder
  5. Tremor (trembling or shaking movements in one or more parts of your body)
  6. Abdominal pain
  7. Constipation
  8. Dysuria (painful or difficult urination)
  9. Faeces discoloured
  10. Haematochezia (passage of stools containing blood)

What are the common drug interactions of Phenytek and Keppra, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Cerebellar atrophy (degeneration of the section of the brain responsible for balance, voluntary muscle movements)
  2. Gingival hypertrophy (overgrowth of gums)
  3. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  4. Ataxia (loss of full control of bodily movements)
  5. Balance disorder
  6. Disturbance in attention
  7. Gait disturbance
  8. Headache (pain in head)
  9. Hypoaesthesia (reduced sense of touch or sensation)
  10. Muscular weakness (muscle weakness)

40-49:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  3. Anxiety
  4. Drug hypersensitivity
  5. Emotional distress
  6. Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
  7. Grand mal convulsion (a type of generalized seizure that affects the entire brain)
  8. Injury
  9. Pain
  10. Skin fibrosis (fibrous tissue formation on skin)

50-59:

  1. Faeces discoloured
  2. Haematochezia (passage of stools containing blood)
  3. Pollakiuria (abnormally frequent passage of relatively small quantities or urine)
  4. Pancreatitis (inflammation of pancreas)
  5. Pleural effusion (water on the lungs)
  6. Abdominal pain
  7. Constipation
  8. Dysuria (painful or difficult urination)

60+:

  1. Cardiac failure
  2. Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
  3. General physical condition
  4. Malaise (a feeling of general discomfort or uneasiness)
  5. Asthenia (weakness)
  6. Drug resistance (reduction in effectiveness of a drug)
  7. Fall

What are the existing conditions these people have? *

  1. Hyperkalemia (damage to or disease of the kidney): 6 people, 26.09%
  2. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 4 people, 17.39%
  3. Pain: 4 people, 17.39%
  4. Nausea And Vomiting: 4 people, 17.39%
  5. Nausea (feeling of having an urge to vomit): 4 people, 17.39%
  6. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 4 people, 17.39%
  7. Muscle Spasms (muscle contraction): 3 people, 13.04%
  8. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 13.04%
  9. High Blood Pressure: 3 people, 13.04%
  10. Multiple Allergies (allergy to multiple agents): 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Phenytek and Keppra?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Phenytek and Keppra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Phenytek:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Keppra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Phenytek and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Keppra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on phenytoin sodium and levetiracetam (the active ingredients of Phenytek and Keppra, respectively), and Phenytek and Keppra (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: